Coexpression of EpCAM, CD44 variant isoforms and claudin-7 in anaplastic thyroid carcinoma.
Anaplastic thyroid cancer is considered to be one of the most aggressive human malignancies, and the mean survival time after diagnosis is approximately six months, regardless of treatments. This study aimed to examine how EpCAM and its related molecules are involved in the characteristics of anapla...
Main Authors: | Toshihiro Okada, Teruo Nakamura, Takayuki Watanabe, Naoyoshi Onoda, Atsuko Ashida, Ryuhei Okuyama, Ken-ichi Ito |
---|---|
Format: | Article |
Language: | English |
Published: |
Public Library of Science (PLoS)
2014-01-01
|
Series: | PLoS ONE |
Online Access: | http://europepmc.org/articles/PMC3984167?pdf=render |
Similar Items
-
EpCAM-claudin-tetraspanin-modulated ovarian cancer progression and drug resistance
by: Zehra Tavsan, et al.
Published: (2020-01-01) -
Matriptase Cleaves EpCAM and TROP2 in Keratinocytes, Destabilizing Both Proteins and Associated Claudins
by: Chuan-Jin Wu, et al.
Published: (2020-04-01) -
EpCAM as Modulator of Tissue Plasticity
by: François Fagotto
Published: (2020-09-01) -
Expression of EpCAM in uveal melanoma
by: Odashiro Alexandre N, et al.
Published: (2006-11-01) -
Biology and clinical relevance of EpCAM
by: Laura Keller, et al.
Published: (2019-05-01)